Yissum - Research Development Company of the Hebrew University

A New Tool to Diagnose and Monitor IBD Using Circadian Gene Expression

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

A New Tool to Diagnose and Monitor IBD Using Circadian Gene Expression
Project ID : 85151

Description of the technology

Category

Life Sciences &Diagnostic

Keywords

IBD, clock circadian ,Colitis, Diagnostic tool, Crohn,

Systemic diseases, Inflammation disease

Current Development stage

General list: TRL5 Technology validated in relevant environment

Application

Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is characterized by chronic relapsing intestinal inflammation. To date several biomarkers are used for the diagnosis of IBD, such as CRP (blood) and Fecal (stool), which are limited due to low specificity and low sensitivity for diagnosing IBD. Therefore, colonoscopy, an invasive, time consuming and costly procedure, remains the gold standard method for diagnosis and monitoring of IBD.

Our invention suggests a new non-invasive and specific IBD diagnostic tool using clock gene and protein expression detected in simple blood samples.

Technology

The proposed invention is a diagnostic tool for IBD and other systemic diseases, which measures the expression of the main circadian clock genes/proteins. These genes/proteins can be measured systemically and therefore hold the potential of being diagnosed and monitored by a simple blood sample.

Our Innovation

  • A specific, fast and non-invasive simple blood test, relying on systemic rather than local markers, with no side effects and complications
  • Diagnostic tool able to:
  • Monitor response to medical drug treatment
  • Follow up patients in remission (between flares), and possibility of intervention and preventive care

  • ELISA-based or gene-expression-based kits can be used at point of care
  • Can be applicable for all systemic diseases

Expected Impact

The researcher’s overall goal is to develop diagnostic ELISA and/or gene expression kits with several clock protein/gene which can diagnose IBD as well as reflect disease state (remission/flare-ups), IBD severity and classification, and monitor the patient’s response to medical treatment. Such a tool can reduce the use of invasive tests along the diagnosed IBD patient’s life.

Next Phase

Develop ELISA as well as gene expression kits that combine several proteins/genes for reliable and specific detection (2 year research)

Intellectual property

Provisional application in preparation

Project manager

Shani Bullock
VP, Business Development, Healthcare

Project researchers

Oren Froy
, HUJI, Faculty of Agricultural, Food and Environmental Quality Sciences, Biochemistry, Food Science and Nutrition,

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Gene - DNA Therapy
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Genetic Engineering / Molecular Biology
  • Life Science & Biotechnology

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.